Rationale: Hypereosinophilic syndrome (HES) is a rare disorder characterized by hypereosinophilia and organ damage. Some cases of HES are caused by the FIP1L1/PDGFRA fusion gene and respond to imatinib. FIP1L1/PDGFRA-positive HES occasionally evolves into chronic eosinophilic leukemia or into another form of myeloproliferative neoplasm; however, the development of a malignant lymphoma is very rare. We present a rare case of angioimmunoblastic T-cell lymphoma (AITL) and HES with the FIP1L1/PDGFRA gene rearrangement.
Patient Concerns: A man in his 30s presented to our hospital with fever, hypereosinophilia, widespread lymphadenopathy, and splenomegaly. Laboratory tests showed hypereosinophilia, increased soluble interleukin-2 receptor, and increased vitamin B12. Positron-emission tomography with F fluorodeoxyglucose (FDG) showed positive FDG uptake in multiple enlarged lymph nodes throughout the body and the red bone marrow. A bone-marrow biopsy showed hypereosinophilia without dysplasia and an increased number of blasts. The FIP1L1/PDGFRA fusion gene was positive upon fluorescence in situ hybridization (FISH) analysis of the peripheral blood. Furthermore, biopsy of a lymph node from the neck revealed restiform hyperplasia of capillary vessels, with small lymphoma cells arranged around the capillaries. Lymphoma cells were positive for CD3, CD4, and CD10, and negative for CD20. Lymphoma cells were also positive for the FIP1L1/PDGFRA fusion gene by FISH analysis.
Diagnoses: From these findings, the patient was diagnosed with HES and AITL with FIP1L1/PDGFRA.
Interventions: After the diagnosis, corticosteroid was administered but was ineffective. Imatinib was then administered.
Outcomes: Imatinib was very effective for treating HES and AITL, and complete remission was achieved in both.
Lessons: This report presents the first case in which the FIP1L1/PDGFRA fusion gene was positive both in peripheral blood and lymph nodes, implying the possibility that the tumor cells acquired the FIP1L1/PDGFRA fusion gene in the early stage of hematopoietic progenitor cell developments. Imatinib was very effective in treating both HES and lymphoma, suggesting that the FIP1L1/PDGFRA fusion gene plays a key role in the pathogenesis of both HES and lymphoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392760 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000008001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Next-generation sequencing RNA fusion panel for the diagnosis of haematological malignancies.
Pathology
November 2024
Department of Haematology, Monash Health, Clayton, Vic, Australia; Department of Diagnostic Genomics, Monash Health, Clayton, Vic, Australia; School of Clinical Sciences, Monash University, Clayton, Vic, Australia. Electronic address:
Haematological malignancies are being increasingly defined by gene rearrangements, which have traditionally been detected by karyotype, fluorescent in situ hybridisation (FISH) or reverse-transcriptase polymerase chain reaction (RT-PCR). However, these traditional methods may miss cryptic gene rearrangements and are limited by the number of gene rearrangements screened at any one time. A next-generation sequencing (NGS) RNA fusion panel is an evolving technology that can identify multiple fusion transcripts in a single molecular assay, even without prior knowledge of breakpoints or fusion partners.
View Article and Find Full Text PDFA case report of right-sided heart failure secondary to JAK2-mutation Loeffler endocarditis.
ESC Heart Fail
December 2024
Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences/Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, People's Republic of China.
Article Synopsis
- Loeffler's endocarditis (LE) is linked to hypereosinophilic syndrome, presenting in a 45-year-old woman with severe right-sided heart failure and an extreme eosinophil count of 20.9 × 10.* -
- Imaging showed significant damage to the right ventricle, and biopsies revealed extensive endocardial fibrosis and eosinophil-rich thrombi, though no specific gene mutations were linked to abnormal blood conditions.* -
- The patient underwent treatment with ruxolitinib, followed by heart transplantation due to irreversible damage, and after a challenging recovery phase, she improved despite facing ICU-acquired weakness and depression.*
Acute myeloid leukemia with fusion gene: 'Pitfalls' in diagnosis.
Hematology
December 2024
Department of Clinical Laboratory, Fuyang People's Hospital, Fuyang, People's Republic of China.
Article Synopsis
- The text discusses a rare case of acute myeloid leukemia (AML) associated with basophilia, emphasizing the challenges in diagnosing this condition due to its rarity and poor prognosis.
- The authors describe their use of various diagnostic methods, including morphological screening, immunotyping, FISH analysis, and RNA sequencing, to accurately identify the type of AML and to guide treatment decisions.
- The study highlights the importance of advanced techniques such as NGS for detecting a broader range of genetic mutations, which can help avoid misdiagnosis and improve treatment outcomes for patients with hematologic malignancies.
Hypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil counts (>1.5 x 10 on two consecutive measurements), which are of myeloid clonal in origin or are driven by excess cytokines. One subtype of HES exhibits the Fip1-like 1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) fusion gene, a gain-of-function mutation resulting in a hyperactive tyrosine kinase.
View Article and Find Full Text PDFMarked eosinophilic atypia in a patient with asthma and myeloid/lymphoid neoplasm with FIP1L1::PDGFRA fusion.
Br J Haematol
July 2024
Department of Pathology, Immunology, and Laboratory Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!